Molecular Changes Evoked by Triethylenetetramine (TETA) Treatment in the Extracellular Matrix of the Heart and Aorta in Diabetic Rats


From the School of Biological Sciences (DG, JL, XC, SYC, SZ, YKC, SGJ, SRJP, GJSC), Faculty of Science, and the Maurice Wilkins Centre for Molecular Biodiscovery (SZ, GJSC) University of Auckland, Auckland, New Zealand, and the Department of Medicine(GDG, GJSC), Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Running title: Molecular changes by TETA treatment in diabetes

Address correspondence and reprint request to:

Professor Garth J.S. Cooper

School of Biological Sciences, University of Auckland,

Private Bag 92019, Auckland, New Zealand.

E-mail: g.cooper@auckland.ac.nz

Text pages: 17
Tables: 1
Figures: 5
References: 36
Words in Abstract: 223
Words in Introduction: 541
Words in Discussion: 1119

ABBREVIATIONS: AGEs, advanced glycation end-products; CAD, coronary artery disease; Ct, threshold cycle; ECM, extracellular matrix; EC-SOD, extracellular superoxide dismutase; ELISA, enzyme-linked immunosorbent assay; GAG, glycosaminoglycan; HS, heparan sulfate; KHB, Krebs-Henseleit bicarbonate buffer; LV, left ventricle; NO, nitric oxide; O$_2^-$, superoxide anion; PAI-1, plasminogen activator inhibitor-1; PCR, polymerase chain reaction; PKC, protein kinase C; ROS, reactive oxygen species; STZ, streptozotocin; TETA, triethylenetetramine; TGF-β1, transforming growth factor-β1; TNF-α, tumor necrosis factor-α.
ABSTRACT

Most diabetic subjects die from cardiac or arterial disease, for which there are limited therapeutic options. Free Cu$^{2+}$ ions are strongly pro-oxidant and chelatable-Cu$^{II}$ is increased in the diabetic heart. We previously reported that treatment by Cu$^{II}$-selective chelation with triethylenetetramine (TETA) evokes elevated urinary Cu$^{II}$ in diabetic rats and humans, in whom it also improved hallmarks of established left ventricular (LV) disease. Here, we treated diabetic rats with TETA and evaluated its ability to ameliorate Cu$^{2+}$-mediated LV and arterial damage by modifying expression of molecular targets that included transforming growth factor (TGF)-β1, Smad4, extracellular matrix (ECM) proteins, extracellular superoxide dismutase (EC-SOD), and heparan sulfate (HS). Eight-week’s TETA treatment significantly improved cardiac diastolic function but not [glucose]$_{plasma}$ in diabetic animals. LV and aortic mRNAs corresponding to TGF-β1, Smad4, collagen types I, III and IV and fibronectin-1, and plasminogen activator inhibitor-1 (PAI-1), were elevated in untreated diabetic animals and normalized following TETA treatment. EC-SOD mRNA and protein, and [HS]$_{tissue}$ were significantly decreased in diabetes and restored by drug treatment. Candidate molecular mechanisms by which TETA could ameliorate diabetic cardiac and arteriovascular disease include suppression of an activated TGF-β/Smad signaling pathway that mediates increased ECM gene expression, and restoration of normal EC-SOD and HS regulation. These findings are relevant to the restoration towards normal by TETA treatment of cardiac and arterial structure and function in diabetes.

More than three-quarters of diabetic patients die from various cardiovascular complications (Sicree et al., 2003). We recently demonstrated that the amount of Cu$^{II}$
that can be extracted from the heart via coronary artery perfusion with triethylenetetramine (TETA) is substantively increased in diabetic rats (Cooper et al., 2004). TETA treatment stimulated urinary Cu^{II} excretion in streptozotocin (STZ)-diabetic rats and type-2 diabetic patients to a greater extent than in matched controls, and restored cardiac structure and function towards normal in both groups (Cooper et al., 2005; Cooper et al., 2004). Specific underpinning mechanisms relating to Cu^{II}-chelation in diseased diabetic cardiac and arterial tissues, however, remain to be elucidated.

Free Cu^{2+} is strongly pro-oxidant in mammalian tissues (Fraústo da Silva and Williams, 2001) and may activate pathways that cause the excessive generation of reactive oxygen species (ROS) such as superoxide (O$_2^-$) in diabetic cardiovascular tissues. There is an increased O$_2^-$ production in the heart and arteries of both animals and humans with diabetes or heart failure. Extracellular superoxide dismutase (EC-SOD/SOD3) is a major antioxidant in mammalian tissues. It is highly expressed and active in blood vessels (Marklund, 1984a), and protection of nitric oxide (NO) is thought to be a major function of EC-SOD (Oury et al., 1996). EC-SOD activity is decreased in arteries of diabetic subjects (Fattman et al., 2003), resulting in increased susceptibility of vascular cells to effects of O$_2^-$ with consequent endothelial dysfunction.

We recently showed that elevation of circulating EC-SOD in type-2 diabetic humans was strongly correlated with an interaction between hemoglobin A$_1c$ and [Cu]$_{plasma}$ (Cooper et al., 2005). Furthermore, Cu^{2+} at high concentrations, suppressed EC-SOD secretion from cultured vascular smooth muscle cells (Stralin et al., 2003). The extracellular content of EC-SOD in blood vessels is associated with the level of heparan
sulfate (HS), a major binding anchor for EC-SOD (Sandstrom et al., 1993). Diabetic status can decrease arterial HS levels (Edwards et al., 2004) and compromise its function by modifying its structure (Vogl-Willis and Edwards, 2004).

Excessive accumulation of extracellular matrix (ECM) proteins and associated myocardial fibrosis are implicated as pathogenic mechanisms in diabetic heart disease (Marklund, 1992). We previously reported that chronic TETA treatment can regenerate the ECM in diabetic rat hearts (Cooper et al., 2004). TGF-β1 stimulates ECM protein accumulation in diabetic tissues by up-regulating expression of corresponding genes or down-regulating those for ECM-degrading enzymes (Roberts et al., 1992). There is evidence for a link between redox stress, TGF-β1 and ECM production (Williams, 1998).

The current study investigated molecular mechanisms by which TETA reverses diabetic heart disease in an STZ model. We show here that oral TETA administration significantly improved diastolic function in diabetic rat hearts. We also show that treatment with TETA suppressed the diabetes-evoked up-regulation of TGF-β1/Smad4, collagens I, III and IV, fibronectin-1 and plasminogen activator inhibitor (PAI)-1 in the LV and aorta of diabetic rats, and that it elevated EC-SOD mRNA and protein expression in these tissues. TETA administration was further shown to restore diabetes-induced decreases of HS levels in both heart and aorta. These results support that TETA reverses diabetic cardiac disease at least in part through enhanced disposal of extracellular O$_2^-$ and suppression of increases in ECM gene expression that may result from up-regulation of the TGF-β/Smad signaling pathway.
Materials and Methods

Induction of Diabetes and Drug Treatment. All studies were approved by relevant ethics and regulatory committees. Male Wistar rats, weighing 220 to 250g, were rendered diabetic by a single intravenous tail vein injection of STZ (Sigma; 55 mg/kg bodyweight) in isotonic saline, as described previously (Cooper et al., 2004). Age-matched control rats were injected with equal volumes of saline (untreated non-diabetic control).

Bodyweights and [glucose]blood were monitored weekly for 16 weeks. After 8 weeks’ diabetes, rats were assigned to one of two groups: untreated diabetic; and TETA-treated diabetic. TETA (20 mg/day-rat) was administered in the drinking water (18 MΩ, Milli Q) as triethylenetetramine dihydrochloride (tiensine, Fluka) or the equivalent molar dose of TETA disuccinate (Protemix, Auckland) for a further 8 weeks. In the HS study, the TETA was administered in the same manner to diabetic and control rats at a dose of 10 mg/day-rat.

Rats were housed (12:12-h light-dark cycle; temperature 22.5°C (range: 20-26); humidity 60% (range 50 - 70)) in like-pairs with ad libitum food (Teklad 2018) and water. Sixteen weeks after STZ injection, rats were anesthetized (halothane, 5%), appropriately heparinized (200 I.U./kg i.v.) and organs excised. Aortas and cardiac LV were either perfused or washed free of blood in ice-cold DEPC-treated phosphate-buffered saline (PBS). Tissues were stored in RNAlater (Ambion) overnight at 4°C, and then at -80°C for subsequent RNA isolation. Portions were also stored at -80°C for parallel protein analyses as well as from additional like-treated rats for HS analysis.

Measurement of Cardiac Function in Rats. Cardiac function was determined as previously detailed in isolated perfused working rat hearts (Cooper et al., 2004).
RNA Isolation and cDNA Synthesis. Total RNA was isolated from LV or aortic tissue using RNA Midi Kits (Qiagen, Valencia, CA). One µg of total RNA was treated with RQ1 RNase-free DNase (Promega) at 37°C for 30 min, and then reverse-transcribed with random hexamers and SuperScript™ III Reverse Transcriptase (Invitrogen).

Real-Time Quantitative PCR Analysis. Messenger RNA levels were compared by real-time quantitative PCR (qPCR) with an ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Reactions were prepared in the presence of the fluorescent dye SYBR green I. The levels of gene expression of the target sequence were normalized to those of an active endogenous control, 18S ribosomal RNA (18S, Ambion) in the same cDNA sample. Table 1 displays a list of primers synthesized by Invitrogen for each gene analyzed. The primers and TaqMan probe employed for type I collagen were proprietary to Applied Biosystems, and so are not listed in Table 1. In PCR reactions, 1.5 and 0.25 ng of cDNA, and 0.5 and 0.1 µM of primers were used for amplification of target genes and 18S rRNA, respectively. After PCR amplification, dissociation curves were constructed and PCR products were subjected to agarose gel electrophoresis to confirm formation of the specific PCR products. The threshold cycle at which the fluorescent signal reaches a particular value was used as a measure of gene expression. The linear range of dilution for target genes and 18S rRNA showed different slopes, indicating different amplification efficiency for control and target genes, and a standard curve method was therefore used. Analysis of mRNA expression was performed as described in User Bulletin #2 (Applied Biosystems) using standard curves prepared from serially-diluted control cDNA samples.
Western Blot Analysis. Frozen aorta was homogenized in ice cold lysis buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 10 mM MgCl₂, 50 mM EDTA, 2 mM DTT and 10% (V/V) glycerol) in the presence of a proteinase inhibitor cocktail (Roche). Homogenate was centrifuged at 13,000g for 20 min at 4°C. The supernatant was isolated, and protein concentration determined with BCA Protein Assay (Pierce, Rockford, IL). Twenty µg protein was separated by gel electrophoresis and transferred to a nitrocellulose membrane. Five µg rat brain tissue extract (Stressgen Bioreagents, Canada) was used as a positive control. Western blots were performed using a rabbit anti-EC-SOD (Phoenix Pharmaceuticals), specific signal was detected with a donkey anti-rabbit IgG-HRP conjugate (Amersham) and ECL™ Plus Western Blotting Detection Reagents (Amersham) according to the manufacturer’s instructions. Epson Perfection 4990 Scanner and SilverFast software (Singapore) were used to scan and evaluate densitometrically the signal on X-ray film.

Enzyme-linked Immunosorbent Assay (ELISA) for HS. HS levels in LV and aorta were assayed using an ELISA kit (Seikagaku, Tokyo, Japan). This antibodies used do not react with other GAGs, including heparin (Yokoyama et al., 1999). Briefly, the assay procedures were performed as follows: Frozen LV or aortic tissue was homogenized in ice-cold PBS buffer, homogenate was centrifuged at 13,000g for 20 min at 4°C, and supernatant was isolated, and protein concentrations determined (BCA). Then, 10 µL of 20 mg/mL actinase E (Kaken Pharmaceuticals, Japan) was added to 100 µL supernatant and incubated at 55°C for 20 h to digest tissue and release bound heparan sulfate from proteins. After incubation, samples were boiled for 5 min, cooled, and centrifuged at 3,000g for 10 min. Then, samples were assayed according to manufacturer’s instruction.
using a 96-well plate. After assay reactions, the plate was read at 450 nm using a microplate reader (SpectraMax 340).

**Statistical Analysis.** Data are expressed as means ± SEM. We planned comparisons for each gene between control and diabetic groups to verify impact of diabetes, and between diabetic and TETA-treated diabetic groups to measure effect of the drug. The unpaired Student’s *t*-test was hence used to determine the significance of between-group gene expression differences (Prism, v4.02). Mixed linear effect models were fitted by restricted maximum likelihood using SPlus v7.0.2 (Insightful) to analyze \((-dP_{LV}/dt)_{\text{mean}}\). One-way ANOVA with post-hoc Tukey’s-test was used to determine the significance of between-group HS concentration differences (Prism, v4.02). *P* values of < 0.05 have been considered significant, and *n* values indicate numbers of replicates.

**Results**

**Selective Cu\textsuperscript{II} Chelation Improved Cardiac Parameters in Diabetic Rats.**

Hyperglycemia occurred within 2 days after STZ administration in all experiments, during which hyperglycemia persisted equivalently in both untreated and TETA-treated diabetic rats. The mean bodyweights of different groups of rats were similar at the time of STZ injection. Bodyweight gain over the 16-week experimental period in TETA-treated diabetic rats was significantly higher than in untreated diabetic rats (*P* < 0.05) (Fig. 1A). Blood glucose concentrations did not differ among groups at the time of STZ injection, nor between TETA-treated and untreated diabetic rats over the 16-week experimental period (Fig. 1B, and data not shown), indicating that the TETA-mediated Cu\textsuperscript{II} chelation did not decrease blood glucose levels in diabetic rats.
Diabetes causes cardiac dysfunction and failure in STZ-diabetic rats (Cooper et al., 2004) and humans (Struthers and Morris, 2002). Diabetic rats showed a significantly higher ratio of cardiac mass to body mass than that of non-diabetic rats (4.48 ± 0.012 x 10^{-3} vs. 2.71 ± 0.015 x 10^{-3}; P < 0.001), showing that they had developed cardiac hypertrophy. This ratio was significantly restored towards normal in diabetic rats that received 8-week oral TETA treatment (4.18 ± 0.078 x 10^{-3}; P < 0.05). Sixteen-week diabetic rats also had lowered (–dP_{LV}/dt)_{mean} (P = 0.017), whereas 8-week TETA treatment improved (–dP_{LV}/dt)_{mean} towards normal (P = 0.022) (Fig. 1C). Thus, consistent with our previous report (Cooper et al., 2004), diabetes caused cardiac hypertrophy and diastolic dysfunction that were substantively ameliorated by TETA treatment. These findings indicate that biochemical changes reported herein reflect structural and functional cardiac changes induced by diabetes and TETA treatment similar to those we previously reported (Cooper et al., 2004).

**ECM Protein Expression (LV and aorta).** To investigate the molecular mechanisms by which TETA improved cardiac structure and function in diabetic rats, we analyzed expression of mRNAs corresponding to major ECM proteins. Expression of collagen I (Fig. 2A), III (Fig. 2B), IV (Fig. 2C), fibronectin-1 (Fig. 2D) and PAI-1 (Fig. 2E) in LV were elevated in diabetes and these increases were suppressed by TETA treatment. Expression of collagens III (Fig. 2F) and IV (Fig. 2G), and fibronectin-1 (Fig. 2H) in the aortas of diabetic rats were also elevated, and these increases were also suppressed to normal by TETA treatment.

**TGF-β1 and Smad4 Expression (LV and aorta).** To further characterize the mechanism by which TETA inhibited the accumulation of ECM proteins in diabetic rats,
we analyzed the mRNA expression of genes involved in the TGF-β/Smad signaling pathway, which elicits stimulation of collagen production and plays a pivotal role in fibrogenesis (Sharma and Ziyadeh, 1995). Expression levels of mRNAs corresponding to TGF-β1 (Fig. 3A) and Smad4 (Fig. 3B) were increased, by 1.9- and 1.4-fold respectively, in LV tissue of diabetic rats compared with non-diabetic controls. In aortic tissue, TGF-β1 (Fig. 3C) and Smad4 (Fig. 3D) mRNA expression levels were similarly increased, by 3.3- and 1.5-fold respectively; TETA treatment significantly reversed the increased expression of these mRNAs in both LV and aorta of diabetic rats (Fig. 3A-D).

**EC-SOD Expression (LV and aorta).** EC-SOD is the only antioxidant enzyme known to be present in several extracellular compartments (Marklund, 1984b). Activation of the TGF-β/Smad signaling pathway reportedly suppresses EC-SOD expression (Marklund, 1992). Moreover, diabetes-induced oxidative stress was reported to stimulate TGF-β-mediated matrix synthesis in renal glomeruli through activation of protein kinase C (PKC)- and advanced glycation endproduct (AGE)-mediated processes (Akahori et al., 2005). Here, we showed that EC-SOD mRNA levels in LV and aorta from diabetic rats at 16 weeks were significantly decreased, by 2.2- and 2.1-fold respectively, when compared with matched control values (Fig. 4A, B). However, 8-weeks’ TETA treatment significantly restored EC-SOD mRNA levels in these diabetic tissues, by 2.8- and 1.8-fold, respectively (Fig. 4A, B). Interestingly, EC-SOD protein expression level in diabetic aorta was lower than that in non-diabetic aorta, which was significantly increased by TETA treatment (Fig. 4C, D).

**HS concentrations (LV and aorta).** HS is the major binding anchor of EC-SOD in extracellular compartments (Sandstrom et al., 1993). It can bind and localize EC-SOD in
the extracellular matrix of blood vessels, where it eliminates ROS and sustains NO bioavailability (Marklund, 2002). HS concentrations in both LV (Fig. 5A) and aorta (Fig. 5B) were significantly lower in diabetic rats than matched controls. TETA treatment significantly increased HS levels in both tissues (Fig. 5A, B), although mean values were still lower than those in non-diabetic controls. TETA-mediated elevations were correspondingly greater in aortic than LV tissue (Fig. 5), consistent with the hypothesis that its renormalizing effects on cardiac HS content could mainly reflect increases in HS content of coronary arteries.

**Discussion**

In the study, we reconfirmed that TETA significantly improved cardiac structure and function in diabetic rats. Consistent with our previous report (Cooper et al., 2004), TETA ameliorated diabetes-evoked LV hypertrophy and diastolic dysfunction without lowering blood glucose (Fig. 1). Here we have shown for the first time that Cu^{II} chelation suppressed diabetes-evoked upregulation of mRNAs corresponding to several ECM proteins, and inhibited diabetes-induced activation of the TGF-β1/Smad signaling pathway. TETA treatment also caused robust increases in mRNA and protein expression of EC-SOD. Furthermore, HS was partially restored by TETA treatment in the heart and aorta of diabetic rats.

Although the pathogenesis of diabetic cardiovascular disease is multi-factorial, tissue fibrosis is one of its main pathological hallmarks and excessive accumulation of ECM is a key consequence thereof. Diabetes causes overproduction of cardiac ECM, which contributes to diastolic dysfunction, and ECM over-accumulation has been
reported in the diabetic rat heart (Martin et al., 2005). Studies have shown that collagen IV and fibronectin coalesce around smooth muscle cells in the aortic media (Sista et al., 2005). In this study, mRNAs corresponding to these major ECM components were increased in experimental diabetes (Fig. 2). TETA normalized levels of collagen IV and fibronectin-1 mRNAs in diabetic rats (Fig. 2). Consistent with this finding, we previously showed that collagen III protein is substantively elevated in LV of diabetic rats and also normalized by TETA treatment (Cooper et al., 2004).

TGF-β1, a potent fibrogenic factor, stimulates collagen synthesis in cultured stellate cells, and over-expression of TGF-β1 in transgenic mice caused hepatic fibrosis (Sanderson et al., 1995). TGF-β-induced collagen production in cultured cardiac fibroblasts was increased by elevated glucose, indicating that TGF-β signaling pathway may play a major role in cardiac fibrosis and dysfunction (Martin et al., 2005). In the current study, we present in vivo evidence for an inhibitory effect of TETA on diabetes-induced over-expression of TGF-β1 and Smad4 mRNA in LV and aorta (Fig. 3). Interestingly, inhibition of TGF-β expression has been reported to be associated with the inhibitory effect of both lung and liver fibrosis by copper-lowering therapy with tetrathiomolybdate (Askari et al., 2004; Brewer et al., 2004; Brewer et al., 2003). Tetrathiomolybdate was also found to suppress nuclear factor kappa B, which in turn controls transcription of many angiogenic cytokines (Brewer, 2005), and to inhibit chronic inflammation (Omoto et al., 2005). We suggest that this inhibition of mRNA expression of TGF-β1 and one of its major downstream signaling components, Smad4, may be an important mechanism by which TETA ameliorates diabetes-induced cardiac and arterial diseases.
PAI-1 is the primary inhibitor of plasminogen activator \textit{in vivo}, and is thought to promote tissue fibrosis (Schnaper et al., 1995). Previous studies have shown that PAI-1, whose promoter contains Smad-binding elements, is significantly induced by TGF-\(\beta\) via Smad activity (Stroschein et al., 1999). PAI-1 mRNA expression was induced by various inflammatory agents including TGF-\(\beta\) (Venugopal et al., 2004). Interestingly, PAI-1 has been shown to directly control TGF-\(\beta\) expression and thereby ultimately regulate ECM production in diabetes (Nicholas et al., 2005). Here, we have provided \textit{in vivo} evidence for the elevated expression of PAI-1 mRNA in diabetic LV, which was ameliorated by TETA treatment (Fig. 2). All the results suggest that two feed-forward cycles of reciprocal stimulation between TGF-\(\beta\)1 and PAI-1 may perpetuate the fibrotic response in diabetic heart disease. Diabetes-evoked activation of both TGF-\(\beta\)1 and PAI-1, which regulate each other’s expression, may create a self-stimulatory cycle that enhances ECM accumulation and tissue fibrosis.

EC-SOD was said to act, at least in part, via down-regulation of the profibrotic TGF-\(\beta\) pathway. Consistently, EC-SOD null mice displayed increased susceptibility to inflammation and pulmonary fibrosis, suggesting that one mechanism by which EC-SOD protects against pulmonary fibrosis is by inhibiting inflammation (Fattman et al., 2003). Here, we found that TETA treatment increased EC-SOD mRNA and artery-associated protein, whereas it suppressed mRNAs corresponding to collagens I, III and IV, and fibronectin-1 in LV and aortic tissue from diabetic rats. TETA-evoked suppression of the activated TGF-\(\beta\)/Smad pathway and suppression of elevated mRNAs corresponding to ECM proteins may be associated with restoration of EC-SOD mRNA and protein. There have been prior suggestions that TNF-\(\alpha\) also affects EC-SOD (Marklund, 1992), but we
did not observe changes in TNF-α in heart and aorta of diabetic rats in this study (data not shown). Our results support the idea that EC-SOD, acting as a TGF-β1 antagonist, may disrupt the vicious cycle of TGF-β1 over-production in cardiovascular fibrosis. Alternatively, suppression of EC-SOD in diabetic LV and aorta could result from activation of the TGF-β/Smad signaling pathway.

We previously reported that plasma EC-SOD was significantly higher in diabetic patients than that in matched control subjects, and that TETA treatment suppressed this elevation and restored circulating EC-SOD to normal (Cooper et al., 2005). Here, we have shown that arterial HS content was lower in rats with insulin-deficient diabetes than in matched controls, which is perhaps the cause of lower artery-bound EC-SOD. One possible explanation for these observations may lie, at least in part, in responses of arterial HS. Since most EC-SOD is bound in blood vessel walls (Marklund, 1984a), a minor release of EC-SOD into the blood may cause a significant increase in circulating EC-SOD, thereby generating a negative association between serum EC-SOD and vascular HS. This observation is consistent with evidence that EC-SOD bound in arterial walls is decreased in diabetic patients (Ciechanowski et al., 2003; Fattman et al., 2003). TETA’s ability to restore HS levels in blood vessels may be a factor underlying our observation that TETA treatment suppresses the elevated serum EC-SOD in diabetic patients (Cooper et al., 2005). Not only can HS localize EC-SOD to improve vascular ROS disposal, but it also has anti-atherogenic properties (Sivaram et al., 1995), to down-regulate fibroblast growth factor (Nugent et al., 1993), and to inhibit arterial smooth muscle cell proliferation (Castellot et al., 1981). TETA may also exert its effects in diabetic heart failure, at least in part, through vascular HS modulation.
In summary, we propose that TETA treatment attenuates extracellular Cu^{2+}-
evoked cardiac and arterial disease, at least in part by suppressing activation of the TGF-
β/Smad signaling pathway and PAI-1 that would otherwise evoke increased ECM protein
production and associated cardiac and arterial fibrosis. In addition, TETA treatment
robustly stimulates expression of EC-SOD, the sole antioxidant enzyme known to
scavenge extracellular O_2^{•-}, thereby enhancing the potential for its disposal (Fig. 4).

TETA also beneficially modified vascular HS, which was compromised by diabetes.
Whether TETA affects HS synthesis or consumption is also under investigation. We also
expect that the results reported here may well be relevant to cardiovascular diseases
associated with other underlying conditions, such as hypertensive heart disease, ischemic
cardiomyopathy and ageing, in which there are metabolic perturbations similar to those
in diabetes.

Acknowledgments

We thank C.A. Tse, K.H. Liu and V. Tintinger for editorial and technical
assistance.
References


Footnotes

The authors have all declared their association with Protemix Corporation, Auckland, New Zealand and San Diego, CA, USA.

This work was supported by grants from the Endocore Research Trust; the Foundation for Research Science and Technology, New Zealand (FoRST); the New Zealand Department of Education through the Maurice Wilkins Centre for Molecular Biodiscovery; the Health Research Council of New Zealand (HRC); and by Protemix Corporation.
Figure Legends

**Fig. 1.** Effect of TETA treatment on A: bodyweight gain; B: blood glucose; and C: \(-\frac{dP_{LV}}{dt}\)mean with increasing preload in isolated perfused working hearts (n = 9-14/group). Eight weeks after diabetes-induction with STZ, rats were treated with TETA (p.o.) for a further 8 weeks. *P < 0.05, **P < 0.001, NS, not significant. In C, \(-\frac{dP_{LV}}{dt}\)mean values were significantly lower in diabetes (P = 0.017) and this effect was partially ameliorated by TETA treatment (P = 0.022). STZ, streptozotocin.

**Fig. 2.** TETA restored to normal A: collagen I; B: collagen III, C: collagen IV; D: fibronectin-1; and E: PAI-1 mRNA levels in LV, as well as F: collagen III; G: collagen IV; and H: fibronectin-1 mRNA levels in the aorta of STZ-diabetic rats (n = 5/group). *P < 0.05, **P < 0.01. STZ, streptozotocin.

**Fig. 3.** Inhibition by TETA of diabetes-induced over-expression of A: TGF-β1; and B: Smad4 mRNA levels in LV, as well as C: TGF-β1; and D: Smad4 mRNA levels in aorta of STZ-diabetic rats (n = 5/group). *P < 0.05, **P < 0.01. STZ, streptozotocin.

**Fig. 4.** TETA restored EC-SOD mRNA levels in A: LV and B: aorta; and C: a representative Western analysis in aorta (protein), of STZ-diabetic rats (n = 5/group). The calculation of protein restoration is shown in D: quantitative densitometric evaluation of EC-SOD protein in the aorta. The density of non-diabetic control was designated as 100%. N.D., non-diabetic; Dia., diabetic; Dia.+T., TETA-treated diabetic;
P.C., positive control (rat brain tissue extract, Stressgen). *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$. STZ, streptozotocin.

**Fig. 5.** TETA partially restored HS levels in A: LV; and B: aorta of diabetic rats ($n = 11$-14/group). N.D., non-diabetic; N.D.+T., TETA-treated non-diabetic; Dia., diabetic; Dia.+T., TETA-treated diabetic. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$. 

This article has not been copyedited and formatted. The final version may differ from this version.
### TABLE 1
Sequences of oligonucleotide primers used for real-time PCR analysis

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer (5’ – 3’)</th>
<th>Reverse primer (5’ - 3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collagen III</td>
<td>TCCCCTGGAATCTGTGAATC</td>
<td>TGAGTCGAATTGGGGAGAAT</td>
</tr>
<tr>
<td>Collagen IV</td>
<td>GGGTTTCCCTTCTTTTCGT</td>
<td>CATGGTGAAATCGCTGTAA</td>
</tr>
<tr>
<td>Fibronectin-1</td>
<td>GAGGCCACCATCACTGGTT</td>
<td>AGTGCATGACATAGATGGTGA</td>
</tr>
<tr>
<td>PAI-1</td>
<td>AGAGCCAATCAACAGGGCAGT</td>
<td>AGGCAAGTGAGGGCTGAAG</td>
</tr>
<tr>
<td>TGF-β1</td>
<td>GGAAAGGGCTCAACACCTG</td>
<td>CAGTTCTTCTCTGTGGAGCTGA</td>
</tr>
<tr>
<td>Smad4</td>
<td>GGTCCGTTAGGTGAATAGCC</td>
<td>CGGAGGTCGTCTACACCAAT</td>
</tr>
<tr>
<td>EC-SOD</td>
<td>CTGGGAGAGCTTGTACGCTG</td>
<td>CACCAGTGACAGGTTGCAGA</td>
</tr>
</tbody>
</table>
FIG. 2

A
LV collagen I mRNA/18S (x10^-2)

B
LV collagen III mRNA/18S (x10^-1)

C
LV collagen IV mRNA/18S (x10^-1)

D
LV fibronectin-1 mRNA/18S (x10^-2)

E
LV PAI-1 mRNA/18S (x10^-3)

F
Aortic collagen III mRNA/18S (x10^-1)

G
Aortic collagen IV mRNA/18S (x10^-1)

H
Aortic fibronectin-1 mRNA/18S (x10^-2)

Non-diabetic  Diabetic  Diabetic + TETA

Non-diabetic  Diabetic  Diabetic + TETA

** * ****
P < 0.1

This article has not been copyedited and formatted. The final version may differ from this version.
FIG. 3

Aortic TGF-β1 mRNA/18S (x10^-2) for different groups:
- Non-diabetic
- Diabetic
- Diabetic + TETA

LV TGF-β1 mRNA/18S (x10^-2) for different groups:
- Non-diabetic
- Diabetic
- Diabetic + TETA

LV Smad4 mRNA/18S (x10^-2) for different groups:
- Non-diabetic
- Diabetic
- Diabetic + TETA

Aortic Smad4 mRNA/18S (x10^-2) for different groups:
- Non-diabetic
- Diabetic
- Diabetic + TETA

Significance:
- * P < 0.1
- ** P < 0.01

This article has not been copyedited and formatted. The final version may differ from this version.
**FIG. 4**

A. LV EC-SOD mRNA/18S (x10^-2)

B. Aortic EC-SOD mRNA/18S (x10^-2)

C. Aortic EC-SOD protein (Relative optical density %)

D. Aortic EC-SOD protein (Relative optical density %)

Legend:
- N. D.: Non-diabetic
- Dia: Diabetic
- Dia + T.: Diabetic + TETA
- P.C.: Positive Control

Significance levels:
- **: p < 0.01
- ***: p < 0.001
- *: p < 0.05

This article has not been copyedited and formatted. The final version may differ from this version.
FIG. 5

This article has not been copyedited and formatted. The final version may differ from this version.

Molecular Pharmacology Fast Forward. Published on September 14, 2006 as DOI: 10.1124/mol.106.028605